---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-23-000004"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:29:37.310771+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems prelim FY2022 revenue $17.0-17.2M; Q4 $4.2-4.4M; cash $140M

## Summary
- FY2022 commercial revenue expected $17.0-17.2M; Q4 revenue $4.2-4.4M, in line with expectations.
- Placed 9 new Growth Direct systems and completed validation of 19 systems in FY2022.
- Ended 2022 with ~$140M cash and investments, providing runway at least into 2026.
- Added new global Top 20 pharma customer in U.S. and large pharma customer in Japan.
- Launched RMBNucleus Mold Alarm software; to present at J.P. Morgan Healthcare Conference Jan 12.

## SEC filing metadata
- accession: 0001380106-23-000004
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/0001380106-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/rpid-20230111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-23-000004
- JSON: https://secwatch.observer/filing/0001380106-23-000004.json
- Plain text: https://secwatch.observer/filing/0001380106-23-000004.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and fiscal year ended December 31, 2022.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Result: preliminary results
  source text: On January 11, 2023, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results for its fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/0001380106-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.